# PDE11A

## Overview
PDE11A is a gene that encodes the enzyme phosphodiesterase 11A, a member of the phosphodiesterase family involved in the hydrolysis of cyclic nucleotides, specifically cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This enzyme plays a critical role in cellular signaling by regulating the intracellular levels of these secondary messengers, thereby influencing various physiological processes such as metabolism, gene expression, and cell proliferation (Levy2011Phosphodiesterase; Fawcett2000Molecular). PDE11A is expressed in multiple tissues, including the brain, prostate, liver, and skeletal muscle, with significant roles in the brain and reproductive system (Kong2022Functional; Kelly2017A). The protein's structure includes conserved catalytic domains and regulatory GAF domains, which are involved in cyclic nucleotide binding and allosteric regulation (Hetman2000Cloning; Yuasa2000Isolation). Variations in the PDE11A gene have been linked to several clinical conditions, including endocrine and reproductive disorders, as well as neurological and psychiatric diseases, underscoring its importance in human health (HannahShmouni2016Alterations; Qin2021Exome).

## Structure
PDE11A is a member of the phosphodiesterase family, characterized by its ability to hydrolyze cyclic nucleotides such as cAMP and cGMP. The protein contains conserved catalytic domains and regulatory regions, including GAF domains that are involved in cyclic nucleotide binding (Hetman2000Cloning; Yuasa2000Isolation). The catalytic domain of PDE11A is highly conserved and shares structural similarities with PDE5, which contributes to cross-reactivity with PDE5 inhibitors (Cichero2013Homology).

PDE11A exists in multiple splice variant isoforms, including PDE11A1, PDE11A2, PDE11A3, and PDE11A4, each with distinct structural features. PDE11A1 is a 490-amino acid protein with a single GAF domain, while PDE11A2 and PDE11A3 have additional N-terminal amino acids that extend the potential cGMP binding region (Hetman2000Cloning; Fawcett2000Molecular). PDE11A4 is the longest variant, with 934 amino acids and two complete GAF domains, as well as phosphorylation sites for cAMP- and cGMP-dependent protein kinases, which are absent in PDE11A3 (Yuasa2000Isolation).

These structural differences among the isoforms suggest variations in their regulatory mechanisms and tissue-specific functions (Yuasa2000Isolation). The presence of GAF domains and phosphorylation sites indicates potential allosteric regulation and post-translational modifications that may influence the enzyme's activity and interaction with other cellular components.

## Function
PDE11A (phosphodiesterase 11A) is an enzyme that plays a crucial role in regulating intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), which are important secondary messengers in cellular signaling pathways. By hydrolyzing these cyclic nucleotides, PDE11A modulates signal transduction processes that affect various cellular responses, including metabolism, gene expression, and cell proliferation (Levy2011Phosphodiesterase; Fawcett2000Molecular).

PDE11A is expressed in multiple tissues, including the brain, prostate, liver, and skeletal muscle, with its activity being particularly significant in the brain and reproductive system (Kong2022Functional; Kelly2017A). In the brain, PDE11A is involved in the formation of social memories and mood stabilization, suggesting its role in modulating behavior and cognitive functions (Kelly2017A). In the reproductive system, PDE11A influences sperm physiology, affecting sperm concentration, motility, and viability (Kong2022Functional).

The enzyme's activity is regulated by its structure, which includes GAF domains that bind cGMP and influence its function. These domains are involved in allosteric regulation, affecting the enzyme's affinity for its substrates and its cellular localization (Yuasa2001Genomic; Kelly2017A). Through these mechanisms, PDE11A contributes to maintaining normal cellular signaling pathways and preventing abnormal cell growth (Levy2011Phosphodiesterase).

## Clinical Significance
Mutations and altered expression of the PDE11A gene have been implicated in a variety of diseases and conditions. PDE11A mutations are associated with adrenocortical tumors, including primary pigmented nodular adrenocortical disease and isolated micronodular adrenocortical disease, which can lead to Cushing's syndrome (HannahShmouni2016Alterations; Kong2022Functional). Specific mutations such as p.R867G and p.R804H have been linked to familial primary bilateral macronodular adrenal hyperplasia (PBMAH) and elevated cAMP levels, suggesting a role in tumor formation (HannahShmouni2016Alterations).

PDE11A is also implicated in testicular germ cell tumors, with rare inactivating variants like K568R and R545X found exclusively in affected individuals (Pathak2015Rare). In the context of Alzheimer's disease, PDE11A variants such as p.Arg202His and p.Leu756Gln have been identified in early-onset cases, contributing to increased Tau phosphorylation through dysregulation of the cAMP/PKA signaling pathway (Qin2021Exome).

Additionally, PDE11A is linked to psychiatric conditions, with knockout mice exhibiting phenotypes related to psychiatric diseases, such as hyperactivity and impaired social behaviors, indicating its role in brain function (Kelly2010Phosphodiesterase). These findings highlight the clinical significance of PDE11A in various endocrine, reproductive, and neurological disorders.

## Interactions
PDE11A interacts with various proteins, influencing its function and regulatory mechanisms. The N-terminal domain of PDE11A4 is involved in oligomerization, which affects the enzyme's affinity for substrates and inhibitors like tadalafil. This domain decreases the affinity of the catalytic site for these molecules, suggesting that it plays a crucial role in modulating the enzyme's activity and interactions (Weeks2007NTerminal).

The oligomerization state of PDE11A isozymes is concentration-dependent, with PDE11A1 existing as a tetramer and PDE11A4 as a dimer. The GAF subdomains, particularly the GAF-B domain, contribute to stable oligomer formation, although they are not required for oligomerization. These structural features influence the regulatory properties and inhibitor potency of PDE11A isozymes (Weeks2007NTerminal).

PDE11A is also implicated in interactions with components of the glutamatergic system, particularly affecting AMPA receptor regulation. In PDE11A knockout mice, changes in AMPA receptor function and associated proteins suggest that PDE11A may interact with these components, influencing neural activity and signaling pathways (Kelly2010Phosphodiesterase).


## References


[1. (HannahShmouni2016Alterations) Fady Hannah-Shmouni, Fabio R. Faucz, and Constantine A. Stratakis. Alterations of phosphodiesterases in adrenocortical tumors. Frontiers in Endocrinology, August 2016. URL: http://dx.doi.org/10.3389/fendo.2016.00111, doi:10.3389/fendo.2016.00111. This article has 21 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fendo.2016.00111)

[2. (Kelly2010Phosphodiesterase) Michele P. Kelly, Sheree F. Logue, Julie Brennan, Jonathon P. Day, Subha Lakkaraju, Lixin Jiang, Xiaotian Zhong, May Tam, Stacey J. Sukoff Rizzo, Brian J. Platt, Jason M. Dwyer, Sarah Neal, Virginia L. Pulito, Michael J. Agostino, Steven M. Grauer, Rachel L. Navarra, Cody Kelley, Thomas A. Comery, Richard J. Murrills, Miles D. Houslay, and Nicholas J. Brandon. Phosphodiesterase 11a in brain is enriched in ventral hippocampus and deletion causes psychiatric disease-related phenotypes. Proceedings of the National Academy of Sciences, 107(18):8457–8462, April 2010. URL: http://dx.doi.org/10.1073/pnas.1000730107, doi:10.1073/pnas.1000730107. This article has 61 citations.](https://doi.org/10.1073/pnas.1000730107)

[3. (Hetman2000Cloning) Joanna M. Hetman, Nicola Robas, Rhona Baxendale, Mark Fidock, Stephen C. Phillips, Scott H. Soderling, and Joseph A. Beavo. Cloning and characterization of two splice variants of human phosphodiesterase 11a. Proceedings of the National Academy of Sciences, 97(23):12891–12895, October 2000. URL: http://dx.doi.org/10.1073/pnas.200355397, doi:10.1073/pnas.200355397. This article has 67 citations.](https://doi.org/10.1073/pnas.200355397)

[4. (Fawcett2000Molecular) Lindsay Fawcett, Rhona Baxendale, Peter Stacey, Collette McGrouther, Ian Harrow, Scott Soderling, Joanna Hetman, Joseph A. Beavo, and Stephen C. Phillips. Molecular cloning and characterization of a distinct human phosphodiesterase gene family: pde11a. Proceedings of the National Academy of Sciences, 97(7):3702–3707, March 2000. URL: http://dx.doi.org/10.1073/pnas.97.7.3702, doi:10.1073/pnas.97.7.3702. This article has 243 citations.](https://doi.org/10.1073/pnas.97.7.3702)

[5. (Cichero2013Homology) Elena Cichero, Pasqualina D’Ursi, Marco Moscatelli, Olga Bruno, Alessandro Orro, Chiara Rotolo, Luciano Milanesi, and Paola Fossa. Homology modeling, docking studies and molecular dynamic simulations using graphical processing unit architecture to probe the type‐11 phosphodiesterase catalytic site: a computational approach for the rational design of selective inhibitors. Chemical Biology &amp; Drug Design, 82(6):718–731, August 2013. URL: http://dx.doi.org/10.1111/cbdd.12193, doi:10.1111/cbdd.12193. This article has 25 citations.](https://doi.org/10.1111/cbdd.12193)

[6. (Levy2011Phosphodiesterase) Isaac Levy, Anelia Horvath, Monalisa Azevedo, Rodrigo Bertollo de Alexandre, and Constantine A Stratakis. Phosphodiesterase function and endocrine cells: links to human disease and roles in tumor development and treatment. Current Opinion in Pharmacology, 11(6):689–697, December 2011. URL: http://dx.doi.org/10.1016/j.coph.2011.10.003, doi:10.1016/j.coph.2011.10.003. This article has 43 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.coph.2011.10.003)

[7. (Yuasa2000Isolation) Keizo Yuasa, Jun Kotera, Kotomi Fujishige, Hideo Michibata, Takashi Sasaki, and Kenji Omori. Isolation and characterization of two novel phosphodiesterase pde11a variants showing unique structure and tissue-specific expression. Journal of Biological Chemistry, 275(40):31469–31479, October 2000. URL: http://dx.doi.org/10.1074/jbc.M003041200, doi:10.1074/jbc.m003041200. This article has 184 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.M003041200)

[8. (Yuasa2001Genomic) Keizo Yuasa, Yutaka Kanoh, Katsuzumi Okumura, and Kenji Omori. Genomic organization of the human phosphodiesterase pde11a gene: evolutionary relatedness with other pdes containing gaf domains. European Journal of Biochemistry, 268(1):168–178, January 2001. URL: http://dx.doi.org/10.1046/j.1432-1327.2001.01866.x, doi:10.1046/j.1432-1327.2001.01866.x. This article has 77 citations.](https://doi.org/10.1046/j.1432-1327.2001.01866.x)

[9. (Kelly2017A) Michy P. Kelly. A Role for Phosphodiesterase 11A (PDE11A) in the Formation of Social Memories and the Stabilization of Mood, pages 201–230. Springer International Publishing, 2017. URL: http://dx.doi.org/10.1007/978-3-319-58811-7_8, doi:10.1007/978-3-319-58811-7_8. This article has 20 citations.](https://doi.org/10.1007/978-3-319-58811-7_8)

[10. (Weeks2007NTerminal) James L. Weeks, Roya Zoraghi, Sharron H. Francis, and Jackie D. Corbin. N-terminal domain of phosphodiesterase-11a4 (pde11a4) decreases affinity of the catalytic site for substrates and tadalafil, and is involved in oligomerization. Biochemistry, 46(36):10353–10364, August 2007. URL: http://dx.doi.org/10.1021/bi7009629, doi:10.1021/bi7009629. This article has 26 citations and is from a peer-reviewed journal.](https://doi.org/10.1021/bi7009629)

[11. (Qin2021Exome) Wei Qin, Aihong Zhou, Xiumei Zuo, Longfei Jia, Fangyu Li, Qi Wang, Ying Li, Yiping Wei, Hongmei Jin, Carlos Cruchaga, Bruno A Benitez, and Jianping Jia. Exome sequencing revealed pde11a as a novel candidate gene for early-onset alzheimer’s disease. Human Molecular Genetics, 30(9):811–822, April 2021. URL: http://dx.doi.org/10.1093/hmg/ddab090, doi:10.1093/hmg/ddab090. This article has 12 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1093/hmg/ddab090)

[12. (Kong2022Functional) Gyeyeong Kong, Hyunji Lee, Thuy-Trang Vo, Uijin Juang, So Kwon, Jisoo Park, Jongsun Park, and Seon-Hwan Kim. Functional characteristics and research trends of pde11a in human diseases (review). Molecular Medicine Reports, August 2022. URL: http://dx.doi.org/10.3892/mmr.2022.12814, doi:10.3892/mmr.2022.12814. This article has 5 citations and is from a peer-reviewed journal.](https://doi.org/10.3892/mmr.2022.12814)

[13. (Pathak2015Rare) Anand Pathak, Douglas R Stewart, Fabio R Faucz, Paraskevi Xekouki, Sara Bass, Aurelie Vogt, Xijun Zhang, Joseph Boland, Meredith Yeager, Jennifer T Loud, Katherine L Nathanson, Katherine A McGlynn, Constantine A Stratakis, Mark H Greene, and Lisa Mirabello. Rare inactivating pde11a variants associated with testicular germ cell tumors. Endocrine-Related Cancer, 22(6):909–917, December 2015. URL: http://dx.doi.org/10.1530/erc-15-0034, doi:10.1530/erc-15-0034. This article has 19 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1530/erc-15-0034)